Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Seung‐Mo Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8888-6007; OpenAlex author ID A5064975394, A5113259294. Sources: OpenAlex.

Their work

Papers
51 (first author 5, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
168
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 1 paper · 2014: 4 papers · 2015: 1 paper · 2016: 3 papers · 2017: 4 papers · 2018: 7 papers · 2019: 2 papers · 2020: 1 paper · 2021: 5 papers · 2022: 6 papers · 2023: 2 papers · 2024: 5 papers · 2025: 2 papers · 2026: 1 paper

Papers 50 of 51

  1. Combined Gemcitabine and Nab-Paclitaxel Treatment Restores Gut Microbiota Homeostasis in an Orthotopic Pancreatic Ductal Adenocarcinoma Mouse Model. Co-author DOI 10.4143/crt.2026.0409↗
  2. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  3. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  4. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  5. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  6. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  7. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1038/s41598-024-52909-4↗
  8. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  9. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Co-author DOI 10.3348/kjr.2023.0521↗
  10. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  11. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  12. Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: … Last author DOI 10.1016/j.humpath.2022.05.018↗
  13. CODA: quantitative 3D reconstruction of large tissues at cellular resolution Co-author DOI 10.1038/s41592-022-01650-9↗
  14. Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Co-author DOI 10.1073/pnas.2119048119↗
  15. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  16. PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer Co-author DOI 10.3389/fphar.2022.890614↗
  17. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  18. Pancreatic cancer pathology viewed in the light of evolution. First author DOI 10.1007/s10555-020-09953-z↗
  19. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  20. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  21. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  22. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications. Last author DOI 10.1016/j.pan.2020.08.015↗
  23. Why is pancreatic cancer so deadly? The pathologist's view. Co-author DOI 10.1002/path.5260↗
  24. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic D… Last author DOI 10.1097/mpa.0000000000001255↗
  25. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  26. High-grade PanIN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the… Co-author DOI 10.1111/his.13629↗
  27. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Co-author DOI 10.1148/radiol.2018180628↗
  28. Precursor Lesions of Pancreatic Cancer. First author DOI 10.1159/000493554↗
  29. FGFR1 expression defines clinically distinct subtypes in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1743-9↗
  30. Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. First author DOI 10.18632/oncotarget.23567↗
  31. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Last author DOI 10.4143/crt.2017.494↗
  32. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Last author DOI 10.1186/s12935-017-0416-8↗
  33. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. Co-author DOI 10.1259/bjr.20160403↗
  34. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Co-author DOI 10.18632/oncotarget.14901↗
  35. Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Co-author DOI 10.21873/anticanres.11374↗
  36. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Co-author DOI 10.18632/oncotarget.11530↗
  37. Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Co-author DOI 10.18632/oncotarget.9009↗
  38. Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma. Co-author PMID 26851005↗
  39. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2015.05.017↗
  40. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Last author DOI 10.1016/j.humpath.2014.06.030↗
  41. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?:… Co-author DOI 10.1097/mpa.0000000000000063↗
  42. Pancreatic cancer induced by in vivo electroporation-enhanced sleeping beauty transposon gene delivery system in mouse. Co-author DOI 10.1097/mpa.0000000000000102↗
  43. Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. Co-author DOI 10.1158/1078-0432.ccr-13-2823↗
  44. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Co-author DOI 10.1097/mpa.0b013e31825b6ab0↗
  45. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-2165↗
  46. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-1075↗
  47. Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2'-deoxycytidine. Co-author DOI 10.1371/journal.pone.0043456↗
  48. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. First author DOI 10.1007/s13193-011-0073-7↗
  49. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-10-3431↗
  50. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. First author DOI 10.1245/s10434-011-1745-9↗

Closest collaborators

The 25 strongest of 168 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Song Cheol Kim · 22 shared papers, 2013–2025 · strength 2.23
  2. Dae Wook Hwang · 13 shared papers, 2017–2025 · strength 1.71
  3. Kyu‐pyo Kim · 12 shared papers, 2014–2025 · strength 1.52
  4. Hyoung Jung Kim · 10 shared papers, 2017–2025 · strength 1.52
  5. Changhoon Yoo · 9 shared papers, 2018–2025 · strength 1.37
  6. Jae Ho Byun · 8 shared papers, 2018–2025 · strength 1.36
  7. Jin Hee Kim · 7 shared papers, 2018–2025 · strength 1.18
  8. Seung Soo Lee · 7 shared papers, 2018–2025 · strength 1.18
  9. Ki Byung Song · 11 shared papers, 2013–2024 · strength 0.99
  10. Se Jin Choi · 5 shared papers, 2022–2025 · strength 0.96
  11. Jong Keon Jang · 5 shared papers, 2021–2025 · strength 0.91
  12. Dong‐Wan Seo · 6 shared papers, 2014–2025 · strength 0.79
  13. Ralph H. Hruban MD · 10 shared papers, 2011–2022 · strength 0.78
  14. Sung Joo Kim · 5 shared papers, 2017–2023 · strength 0.63
  15. You‐Na Sung · 5 shared papers, 2018–2024 · strength 0.56
  16. Baek‐Yeol Ryoo · 5 shared papers, 2017–2024 · strength 0.51
  17. Eunsung Jun · 4 shared papers, 2016–2026 · strength 0.49
  18. Dong Wan Seo · 3 shared papers, 2018–2025 · strength 0.46
  19. Michael Goggins · 10 shared papers, 2011–2021 · strength 0.43
  20. Sang Soo Lee · 5 shared papers, 2014–2024 · strength 0.42
  21. Lodewijk A.A. Brosens · 4 shared papers, 2019–2022 · strength 0.40
  22. Do Hyun Park · 3 shared papers, 2018–2024 · strength 0.38
  23. Tae Jun Song · 3 shared papers, 2018–2024 · strength 0.38
  24. Suhwan Chang · 5 shared papers, 2016–2022 · strength 0.37
  25. Yejong Park · 2 shared papers, 2024 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.